

Rudolf Schicho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5136833/publications.pdf>

Version: 2024-02-01

53
papers

2,025
citations

218677

26
h-index

254184

43
g-index

53
all docs

53
docs citations

53
times ranked

3379
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-Mediated Neutrophil Polarization and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3218.	4.1	20
2	The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice. <i>British Journal of Pharmacology</i> , 2021, 178, 1234-1248.	5.4	10
3	Identification of Novel Low-Density Neutrophil Markers Through Unbiased High-Dimensional Flow Cytometry Screening in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 703846.	4.8	17
4	Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-17.	4.0	9
5	Monoacylglycerol lipase deficiency in the tumor microenvironment slows tumor growth in non-small cell lung cancer. <i>Oncotarget</i> , 2021, 10, 1965319.	4.6	10
6	Carboxylesterase 2 proteins are efficient diglyceride and monoglyceride lipases possibly implicated in metabolic disease. <i>Journal of Lipid Research</i> , 2021, 62, 100075.	4.2	23
7	The Immune Endocannabinoid System of the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8929.	4.1	28
8	IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils. <i>Oncotarget</i> , 2020, 9, 1776059.	4.6	43
9	Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00120.	2.5	42
10	Cannabinoids in Gynecological Diseases. <i>Medical Cannabis and Cannabinoids</i> , 2019, 2, 14-21.	3.3	11
11	Involvement of EP2 and EP4 Receptors in Eosinophilic Esophagitis: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2806-2814.	2.3	4
12	Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2358.	3.3	60
13	GPR55-Mediated Effects in Colon Cancer Cell Lines. <i>Medical Cannabis and Cannabinoids</i> , 2019, 2, 22-28.	3.3	4
14	Cellular localization and regulation of receptors and enzymes of the endocannabinoid system in intestinal and systemic inflammation. <i>Histochemistry and Cell Biology</i> , 2019, 151, 5-20.	1.7	24
15	Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 794-797.e10.	2.9	11
16	DP1 receptor signaling prevents the onset of intrinsic apoptosis in eosinophils and functions as a transcriptional modulator. <i>Journal of Leukocyte Biology</i> , 2018, 104, 159-171.	3.3	14
17	G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. <i>International Journal of Cancer</i> , 2018, 142, 121-132.	5.1	49
18	Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome. <i>Blood Cancer Journal</i> , 2018, 8, 79.	6.2	4

#	ARTICLE	IF	CITATIONS
19	Medical Cannabis and Cannabinoids: An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon?. <i>Medical Cannabis and Cannabinoids</i> , 2018, 1, 28-35.	3.3	6
20	Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. , 2017, 175, 35-46.		105
21	Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 329-337.	3.0	70
22	The Role of PGE2 in Alveolar Epithelial and Lung Microvascular Endothelial Crosstalk. <i>Scientific Reports</i> , 2017, 7, 7923.	3.3	35
23	Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation. <i>Scientific Reports</i> , 2017, 7, 8030.	3.3	22
24	New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. <i>European Journal of Cancer</i> , 2017, 83, 56-70.	2.8	82
25	Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. <i>Oncotarget</i> , 2017, 8, 101224-101243.	1.8	34
26	The Endocannabinoid System in Carcinogenesis. , 2017, , 1-10.		0
27	Oxidized plasma albumin promotes platelet-endothelial crosstalk and endothelial tissue factor expression. <i>Scientific Reports</i> , 2016, 6, 22104.	3.3	22
28	Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. <i>Handbook of Experimental Pharmacology</i> , 2016, 239, 343-362.	1.8	15
29	Eosinophils Contribute to Intestinal Inflammation via Chemoattractant Receptor-homologous Molecule Expressed on Th2 Cells, CRTH2, in Experimental Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1087-1095.	1.3	25
30	Urinary metabolites as noninvasive biomarkers of gastrointestinal diseases: A clinical review. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 459.	2.0	16
31	Endocannabinoids and the Digestive Tract and Bladder in Health and Disease. <i>Handbook of Experimental Pharmacology</i> , 2015, 231, 423-447.	1.8	29
32	Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 184-193.	2.4	38
33	Cardiovascular Complications in Inflammatory Bowel Disease. <i>Current Drug Targets</i> , 2015, 16, 181-188.	2.1	56
34	Opposing Roles of Prostaglandin D2 Receptors in Ulcerative Colitis. <i>Journal of Immunology</i> , 2014, 193, 827-839.	0.8	28
35	Cannabis Finds Its Way into Treatment of Crohn's Disease. <i>Pharmacology</i> , 2014, 93, 1-3.	2.2	24
36	Patients with IBD find symptom relief in the Cannabis field. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 142-143.	17.8	13

#	ARTICLE	IF	CITATIONS
37	The urea decomposition product cyanate promotes endothelial dysfunction. <i>Kidney International</i> , 2014, 86, 923-931.	5.2	46
38	O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2013, 91, 449-458.	3.9	31
39	Metabolomics. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 378-383.	2.3	48
40	A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. <i>Neuropharmacology</i> , 2013, 71, 255-263.	4.1	64
41	A Selective Antagonist Reveals a Potential Role of G Protein-Coupled Receptor 55 in Platelet and Endothelial Cell Function. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 54-66.	2.5	79
42	Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice. <i>Pharmacology</i> , 2012, 89, 149-155.	2.2	69
43	Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by ¹ H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and Healthy Individuals. <i>Journal of Proteome Research</i> , 2012, 11, 3344-3357.	3.7	200
44	A potential role for GPR55 in gastrointestinal functions. <i>Current Opinion in Pharmacology</i> , 2012, 12, 653-658.	3.5	50
45	Alternative Targets Within the Endocannabinoid System for Future Treatment of Gastrointestinal Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 377-383.	1.7	29
46	Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors. <i>European Journal of Immunology</i> , 2011, 41, 2379-2389.	2.9	33
47	The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1651-1664.	1.9	95
48	Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 193-207.	3.1	17
49	Quantitative Metabolomic Profiling of Serum and Urine in DSS-Induced Ulcerative Colitis of Mice by ¹ H NMR Spectroscopy. <i>Journal of Proteome Research</i> , 2010, 9, 6265-6273.	3.7	87
50	Nociceptive transmitter release in the dorsal spinal cord by capsaicin-sensitive fibers after noxious gastric stimulation. <i>Brain Research</i> , 2005, 1039, 108-115.	2.2	40
51	Increased expression of TRPV1 receptor in dorsal root ganglia by acid insult of the rat gastric mucosa. <i>European Journal of Neuroscience</i> , 2004, 19, 1811-1818.	2.6	105
52	Increased expression of GAP-43 in small sensory neurons after stimulation by NGF indicative of neuroregeneration in capsaicin-treated rats. <i>Regulatory Peptides</i> , 1999, 83, 87-95.	1.9	14
53	Nerve growth factor stimulates synthesis of calcitonin gene-related peptide in dorsal root ganglion cells during sensory regeneration in capsaicin-treated rats. <i>Neuroscience Research</i> , 1999, 35, 183-187.	1.9	15